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DEDICATORY ESSAY
ADVENTURES WITH LORI ANDREWS
George J. Annas*
The subtitle of Lori Andrew's autobiographical The Clone Age is
"Adventures in the New World of Reproductive Technology."' This may
seem an odd characterization of the life of a legal scholar, but adventures
is just right to chronicle the life of this academic legal activist. Lori's legal
adventures began at Yale Law School and continue in Chicago, where she
was a researcher at the American Bar Association for over a decade and is
now professor of law at Chicago-Kent College of Law and Director of the
Institute for Science, Law and Technology. Her adventures in health law
can also be dated from the day she took her bar examination which was,
perhaps not coincidentally, the same day the world's first "test-tube baby,"
Louise Brown, was born. The new reproductive technologies have not
provided her only health law subject, nonetheless, the legal issues they
have gestated have been the primary focus of her work. This area of health
law even has a new name: "reprogenetics," denoting the marriage of
reproductive technology and genetic technology.
Throughout her legal career, Lori has been involved in exotic litigation.
At first, it was to enhance and protect the infertility industry, including a
successful challenge to an Illinois statute that de facto prohibited IVF.
More recently it has been to protect the interests of patients, such as an
ongoing suit against a researcher and hospital for their restrictive
patenting of the Canavan gene. In the lawsuit, she represents families who
provided their DNA for the research. Lori has also done mainstream,
foundational scholarly work that has been widely acclaimed even by
conservative medical professionals. Two examples are illustrative of her
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contributions. The first is in the field of genetics. She was coeditor of the
Institute of Medicine's 1994 path-breaking report entitled Assessing
Genetic Risks: Implications for Health and Social Policy, which helped set
the research and policy agenda for genetic testing for the past decade and
which remains the single most authoritative text on legal and ethical issues
involving genetic screening and testing.2 Her personal views on these
matters are well-articulated and solidly defended in her own 2001 book,
Future Perfect: Confronting Decisions About Genetics.
The second example is from the burgeoning field of patient safety.
When the Institute of Medicine produced perhaps its best-known recent
report on patient safety and medical errors, To Error is Human: Building a
Safer Health System,' the Institute's Committee on Quality of Health Care
in America relied heavily on an empirical study of medical errors
conducted by Lori and her colleagues As the Committee notes in the
report, her study
[O]f 1,047 patients admitted to two intensive care units and one
surgical unit at a large teaching hospital, 480 (45.8 percent) were
identified as having had an adverse event, where adverse event
was defined as 'situations in which an inappropriate decision was
made when, at the time, an appropriate alternative could have
been chosen." For 185 patients (17.7 percent), the adverse event
was serious, producing disability or death. The likelihood of
experiencing an adverse event increased about six percent for
each day of hospital stay.
The Andrews study, the only prospective study of medical errors in the
literature, showed that "adverse events" are much more common than
most physicians and patients think, and also that other studies were likely
to have underestimated them because they set too high a threshold for
harm, too high a threshold for preventability, and included only errors that
were documented in the medical record The policy implications, that
2. Committee on Assessing Genetic Risks, Institute of Medicine, ASSESSING
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medical errors are very frequent and that we must significantly reduce
them to protect the lives and health of patients, are obvious.
Given Lori's reputation not only among her peers (who presented her
with the Jay Healey Health Law Teachers Award in 2002), but among
physicians and genetic researchers as well, it is not surprising that in 1995,
when Nancy Wexler's five-year term ended, she was elected only the
second chair of the ELSI (ethical, legal and social implications) Working
Group of the Human Genome Project. Every year brings new ethical and
legal controversies to genetics, and the ELSI Working Group was meant
to anticipate them, analyze them and devise strategies for confronting
them. What Lori did not know, but was about to learn, is that the job of
the ELSI working group had been quietly transformed from critical
thinker to cheerleader by the new head of the NIH Genome Center, Dr.
Francis Collins. In her words:
As the months passed, I noticed a disturbing trend. The ELSI
Working Group was given no budget of its own; instead we had
to ask Collins and his staff for funding. Every time we planned
an activity that might lead to more people getting genetic tests or
participating in genetic research-such as protecting genetic
privacy-we were given a blank check. But each time we
planned an activity that called into question the power of genetic
testing-such as a study of the problems of using genetics to
predict intelligence, criminality, or certain psychiatric
disorders-we were told that the Genome Center didn't have
enough money to fund it.8
Worse than that, when it became apparent that even the NIH and the
Department of Energy, the cosponsors of the ELSI Working Group, did
not want to hear from ELSI about their own internal ethical conduct, Lori
resigned (in February 1996). Resignation was unprecedented, and she
remains the only person ever to resign as the chair of a major federal
bioethics panel. Her resignation was a loud and clear statement that the
emperor had no clothes, and that no one outside NIH could any longer
take the group seriously as an independent ethical voice. James Watson,
the first head of the Genome Project who had always taken credit for
forming the ELSI Working Group, later explained publicly that as far as
he was concerned the group was always meant to act as ethical cover for
the project, and never to do serious ethical or legal work. In Watson's
words, "I wanted a group that would talk and talk and never get anything
done, and if they did do something, I wanted them to get it wrong. I
8. THE CLONE AGE, supra note 1 at 195.
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wanted as its head Shirley Temple Black."9 With Lori neither Watson nor
Collins got their wish. Instead they got that all-too-rare academic who was
willing to stand up to scientific and government power and say, "I won't
play your game by your self-serving rules."
Most recently Lori has found herself in the middle of perhaps the two
most contentious contemporary issues in international health law and
bioethics: the patenting of human genes, and human cloning. In neither is
she bashful. On patenting genes she persuasively and concisely
summarizes her position as follows:
In my view, the decision to allow patents on human genes was
inappropriate, both legally and as a matter of sound policy. The
useful properties of a gene's sequence.. .are not ones that
scientists have invented, but instead are natural, inherent
properties of the genes themselves. Moreover, in my opinion,
gene patents do not meet the criteria of nonobviousness,
because, through in silico analysis, the function of human genes
can now be predicted on the basis of their homology to other
genes. In addition, as a matter of policy, human nucleotide
sequences should not be patentable, even if their function is
known, because such scientific information should be available
to all.V0
As to human cloning, I have recently had the pleasure of working with
her on a draft of an international treaty to outlaw not only reproductive
cloning (there is universal agreement from the countries of the world on
this), but also attempts to alter the genetic characteristics of human
embryos (to produce inheritable alterations). Lori's work in this field has
been informed not only by science and public policy, but also by her
interactions with the world's would-be cloners. Richard Seed, the Chicago
physicist turned cloning promoter, for example, announced his intention
to clone to the world at a conference Lori chaired at Chicago-Kent Law
School. And when the head of his own religion, known as Rael,
announced that little, green extraterrestrials had told him it was his job to
develop human cloning on earth, Lori went to Canada to interview him.
She met with Rael and his science director, Brigitte Bosselier at the
UFO Caf6 in UFOland, a Raelian theme park. As Lori describes the
scene: "We are sitting at a table with a plastic tablecloth with a design of
pumpkins, artichokes and corn. The vaguely Halloween motif of the
tablecloth captures the spirit of the meeting. Brigitte Bosselier is dressed
9. Id. at 206.
10. Lori B. Andrews, Genes and Patent Policy: Rethinking Intellectual
Property Rights, 3 NATURE REV. GENETICS 803,803 (2002).
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like Cleopatra. Rael is dressed in a white Elvis jumpsuit." Lunatic false
prophet fantasy of course, but as she explores the themepark's twenty-six
foot tall replica of DNA in a room shaped like a human cell, Lori muses,
"I am struck by how everything, except the flying saucer itself, looks like
part of the educational material from the Human Genome Project."" Her
observation prompts me to make another: would-be human cloners have
so far succeeded only in cloning press conferences, and would-be creators
of genetic-based medicines have so far succeeded only in patenting gene
sequences. Hype springs eternal.
Meanwhile, back on the planet earth, Lori and I have suggested
language for a proposed international "Convention on the Preservation of
the Human Species" that would outlaw all efforts to initiate a pregnancy
by using either intentionally modified genetic material or human
replication cloning.'2 This treaty, we believe, would be a critical first step
toward developing a global mechanism to assess and control all potentially
devastating new biotechnologies - from xenografts to novel organisms to
nanotechnologies, technologies that could threaten the survival of the
human species. The United Nations is currently locked in a debate about
whether to outlaw asexual reproductive cloning (sometimes called "baby-
making cloning") only or to outlaw research cloning (the making of cloned
human embryos to produce stem cells for potentially therapeutic uses) as
well. The issue of inheritable genetic alterations has yet to be addressed
directly at the UN, but will have to be, and ultimately for the same
reasons.
Banning human reproductive cloning is an ethically defensible and
legally-enforceable line to draw that can both permit legitimate medical
research and prevent a quick slide to a posthuman future:
... these interventions would require massive dangerous and
unethical human experimentation, cloning would inevitably be
bad for the resulting children by restricting their right to an
'open future,' cloning would lead to a new eugenics movement
for 'designer children' (because if an individual could select the
entire genome of their future child, it would seem impossible to
prohibit individuals from choosing one or more specific genetic
characteristics of their future children), and it would likely lead
11. THE CLONE AGE, supra note 1, at 242.
12. George J. Annas, Lori B. Andrews & Rosario M. Isasi, Protecting the
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to the creation of a new species or subspecies of humans,




Lori ends The Clone Age with a meditation on a speech she gave in
Dubai on cloning to a group of armed Muslims who ultimately decided it
was OK to clone men. As she reflects on their stance, she contemplates
cloning from the perspective of her life of working on the legal aspects of
the new reproductive technologies, and concludes that cloning is a good
place to draw the line, for society to reverse the burden of proof and
finally require the scientists to provide reasons why what they want to do
is good for society, and how its benefits can be maximized and its harms
minimized before they proceed. In her words, "Perhaps the main
objection I had to cloning was it replicates everything that was troubling
about reproductive technologies: excessive commercialization, reckless
experimentation on women, procedures undertaken without consent,
unmonitored physical and psychological risks." She continues, apologizing
for the support she has provided to the infertility industry in the past, "My
speech at Dubai was a mea culpa. I had helped make reproductive
technologists invincible, and facing human cloning was like greeting
Frankenstein's monster for the first time. The creation had gone amok. I
needed to draw the line here to atone."
1 4
Catholics, of course, understand confession and penance. Readers of
Lori's wide-ranging work can decide for themselves if atonement is
indicated. In my own view no apology is necessary. Instead, praise for a
human rights champion who has entered the arena as an experienced and
wiser adventurer is in order-as is dedicating this issue of the Journal of
Contemporary Health Law and Policy to her.
13. Id. at 161-62.
14. THE CLONE AGE, supra note 1, at 258.
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